Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and accelerate the development and future commercialization of its nPulse Cardiac Catheter Ablation System.

Spruce Biosciences Inc. (NASDAQ:SPRB) is one of the best hot stocks to buy according to analysts. On March 9, Spruce Biosciences appointed Dale Hooks as Chief Commercial Officer to lead the company’s transition toward its next phase of growth.

Dare Bioscience Inc. (NASDAQ:DARE) said it has received an updated Notice of Award from the U.S. National Institutes of Health extending support for its DARE-PTB1 intravaginal ring program through November 2026.

Sabrina Martucci Johnson, President and CEO of Daré Bioscience, discusses FDA clearance of the IND for DARE-HPV, the planned Phase 2 clinical

“Niagen IV is now offered at over 900 clinics nationwide, including the new iCRYO locations,” stated Rob Fried, CEO of Niagen Bioscience. “This milestone highlights the growing recognition of Niagen IV and injections as essential tools for supporting ...

Fourth Quarter 2025 Revenues of $23.7M and Gross Margin of 59.7%Full Year 2025 Revenues of $86.6M and Gross Margin of 57.7%Interim CFO Mark Frost Appointed CFO on Permanent BasisIntroduces Full Year 2026 Guidance which Reflects Anticipated Revenue Growth Driven by New Products for Translational Science HOLLISTON,

Cogent Biosciences Inc. (NASDAQ:COGT) is one of the best multibagger stocks to invest in according to billionaires. On February 17, Cogent Biosciences released the earnings report for 2025 and entered 2026 with significant regulatory momentum following three positive pivotal trials for its lead candidate,

Octave Bioscience, Inc. is a commercial stage precision care company pioneering biomarker-driven solutions for neurodegenerative diseases, with initial focus on Multiple Sclerosis, and Parkinson’s Disease in partnership with Michael J. Fox Foundation.

Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat

NEW YORK, Jan. 6, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Skye Bioscience, Inc. ("Skye Bioscience, Inc." or the "Company") (NASDAQ: SKYE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses ...